Navigation Links
CSL Behring Partners with Pro Supercross Racer Carl Schlacht to Encourage Those with Primary Immunodeficiency to be a "ChamPIon"
Date:12/13/2012

KING OF PRUSSIA, Pa., Dec. 13, 2012 /PRNewswire/ -- CSL Behring has teamed up with Professional Supercross racer Carl Schlacht to launch www.IamaChamPIon.com. This new online resource is part of the I am a ChamPIon campaign, a partnership that aims to raise awareness of primary immunodeficiency disease (PI or PIDD) while encouraging those with the condition to pursue their dreams despite the challenges that PI can pose. 

"PI is a genetic disorder that can have a dramatic impact on a person's ability to participate in daily activities due to a weakened immune system that leaves him or her vulnerable to common infections. If PI is left untreated, infections can occur – some severe enough to cause permanent and irreversible organ damage," said Dr. John Sleasman, Chief of the Division of Pediatric Allergy, Immunology and Rheumatology at the University of South Florida. "While the condition is not curable, immunoglobulin treatments can help supplement the immune system to allow patients to lead active lives."

Carl is just one of approximately 250,000 individuals (or one in 1,200) diagnosed with PI in the United States. Race fans watching Carl perform high flying jumps and difficult maneuvers would never know that he requires a weekly subcutaneous infusion (i.e., under the skin) of immunoglobulin to manage his condition, which helps him stay healthy to compete at the professional level.

"Growing up I didn't know anyone else affected by primary immunodeficiency," said Carl, who was diagnosed with PI at a year old. "For this reason, I am encouraging everyone affected by PI to visit www.IamaChamPIon.com and post their 'ChamPIon' story. Collectively, we can support and inspire each other to pursue our dreams." 

In addition to providing an outlet for people with PI to share their stories, the
'/>"/>

SOURCE CSL Behring
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CSL Behring Data Shows 4-Factor Prothrombin Complex Concentrate Is As Effective and a More Rapid Treatment for Vitamin K Antagonist Reversal Than Current Standard of Care
2. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
3. Medical Experts Who Participated in CSL Behrings Key Issues Dialogue Prefer Albumin for Fluid Management
4. CSL Behring Awards LEAD Grant to Patient Organizations to Educate Constituents on State Insurance Exchanges
5. CoreLab Partners, Medical Image Assessment Experts, Announces Its Entry Into the Early Alzheimers Imaging Market Space
6. Veterinary Bioscience Institute (VBI) and a-tune software, Inc. Partnership
7. Chimerix To Present At Therapeutic Area Partnerships Meeting
8. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
9. Mangrove Partners Agrees to Support Amended Transaction Between Nabi Biopharmaceuticals and Biota Holdings
10. Bluechiip Signs Strategic Partnership with Gentris Corporation
11. UBM Announces Partnership Agreement With Trade Organisation - SIPPO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... March 30, 2015  Heidrick & Struggles (Nasdaq: HSII ... leadership consulting and culture shaping worldwide, today ... to lead its global Healthcare and Life Sciences practice. ... Sciences, Mitchell will lead a team of more than 80 ... and Asia serving clients ...
(Date:3/30/2015)... US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; NASDAQ: ... University, on March 27 released pre-clinical data on experimental ... oral presentation by Professor Gil Mor MD ... Annual Scientific Meeting of the Society of Reproductive ... In both in vitro and in animal ...
(Date:3/30/2015)... March 30, 2015    Intrexon Corporation ... biology, and Merck Serono, the biopharmaceutical business of ... today announced an exclusive strategic collaboration and license ... T-cell (CAR-T) cancer therapies. This collaboration advances Merck ... that modulate the immune system,s natural ability to ...
(Date:3/30/2015)... 30, 2015 Immunocore Limited, ... to treat cancer, viral infections and autoimmune disease, ... John Bell , the Regius Professor of Medicine ... for the Strategic Coordination of Health Research, to ...      (Photo: http://photos.prnewswire.com/prnh/20150330/736483 ) , ...
Breaking Biology Technology:Heidrick & Struggles Strengthens Leadership of Healthcare - Life Sciences Practice 2Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5
... June 16 Naviscan PET Systems(R), a company,specializing ... the Society of Nuclear Medicine,s Annual Meeting, new ... cancer management. The PEM,Flex(TM) Solo II is a ... for the breast application known as positron,emission mammography, ...
... Medullary Thyroid Cancer Planned to Initiate This Summer, ... Inc. (Nasdaq: EXEL ) announced today that ... (FDA) have reached agreement on the phase 3,registration ... targeting,MET, RET, and VEGFR2, via the Special Protocol ...
... NDC #58177-320-04 & 58177-330-04 ... Lot Numbers listed below, ST. ... recalled specific additional lots of morphine,sulfate 60 mg extended release tablets, ... a precaution, due to the,possible presence of oversized tablets. Oversized tablets ...
Cached Biology Technology:Naviscan's PEM Flex(TM) Detects Smallest Cancers Better Compared to MRI in an Independent Study 2Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 2Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 3Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 4Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 5ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 2ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 3ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 4
(Date:3/19/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet ... on Washington DC,s Fox 5 News ... Next Great Thing", host Laura Evans calls the ... really big breakthrough in mobile payment.,  Award-winning ...
(Date:3/17/2015)... 17, 2015 MedNet Solutions , ... clinical study management systems, is pleased to announce ... ARENA,s Outsourcing in Clinical Trials Southeast conference – ... an excellent forum for MedNet to showcase ... software-as-a-service (SaaS) eClinical technology platform. We ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation (OTCQX: ... exhibition for service robots ever held in ... place on May 11-13, 2015 at the Javits ... for the event include: Acorn Product Development; Axis ... Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya Systems ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... Brine water that flows back from gas wells in ... times more salty than seawater, with high contents of ... consistent with brines formed during the Paleozoic era, a ... Penn State,s Department of Geosciences found. The study indicates ...
... of Energy,s National Renewable Energy Laboratory (NREL) will partner ... a five-year, $7 million effort to economically produce drop-in ... the federal laboratory announced today. The work will ... (CRADA) between NREL and Johnson Matthey. "It,s a ...
... The Hass Avocado Board (HAB) is supporting ... benefits of consuming fresh avocados to human health ... investigate the relationship between avocado consumption and risk ... in weight management and diabetes, and avocados, ability ...
Cached Biology News:Analysis of Marcellus flowback finds high levels of ancient brines 2NREL and Johnson Matthey announce 5-year collaboration on biofuels 2Hass Avocado Board study published in Food & Function journal 2
... protein A media yield highly purified ... to analysis of other immunoglobulin classes, ... purification. Protein A binds to the ... from mammalian species. This ready-to-use, bottled ...
... standard is a new tuning and calibration ... mass spectrometry. Accumix is a lyophilized ... coverage for both tuning and calibration of ... and Fourier transform mass spectrometers. Direct ...
Determine relative degree of protein binding to phosphoinositides...
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
Biology Products: